FASTnet: una piattaforma nazionale per il test EGFR a favore del paziente e del clinico

Translated title of the contribution: FASTnet: A national platform for EGFR testing in favour of the patient and the clinician

Francesca Fenizia, Carmine Pinto, Gaetano De Rosa, Massimo Barberis, Antonio Marchetti, Nicola Normanno

Research output: Contribution to journalArticle

Abstract

During the last decade, new drugs able to interfere with specific neoplastic processes have been developed. Therefore, the possibility of creating a personalized therapeutic scheme, based on the molecular alterations activated in each single tumor, is becoming a clinical reality. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung tumor, representing about 80% of pulmonary cancers. Following the discovery of the role of EGFR gene in tumor growth and development and, later, of activating mutations of this gene, new targeted therapies have been introduced in clinical practice, namely inhibitors of the EGFR tirosin-kinase domain (TKI). First line treatment with TKIs is considered the optimal therapy in patients with metastatic or locally advanced EGFR-M+ NSCLC. For this reason, it is crucial to evaluate EGFR mutational status to identify the most suitable therapeutic approach. The EGFR FASTnet program, started in 2010 with the support of AstraZeneca, is a national network designed to facilitate the exchange of biological material, clinico-pathological data and diagnostic reports between medical oncologists, primary pathologists and referral laboratories through a dedicated website (www.egfrfastnet. it), a call-center and a courier. Starting from July 2010, 12.893 FASTnet forms have been completed and, up to date, 677 oncologists, 153 primary pathologists and 25 analysts are registered to the network and give their active contribute to the mutational analysis workflow. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology - Italian division of International Academy of Pathology (SIAPeC-IAP) have full access to the anonymous EGFR FASTnet database that provides relevant information on molecular pathology in lung cancer in Italy.

Original languageItalian
Pages (from-to)32-36
Number of pages5
JournalRassegna di Patologia dell'Apparato Respiratorio
Volume30
Issue number1
Publication statusPublished - Jan 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
erbB-1 Genes
Neoplastic Processes
Therapeutics
Neoplasms
Medical Oncology
Molecular Pathology
Workflow
Growth and Development
Italy
Phosphotransferases
Referral and Consultation
Databases
Pathology
Lung
Mutation
Pharmaceutical Preparations
Genes
Pathologists

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Pulmonary and Respiratory Medicine

Cite this

FASTnet : una piattaforma nazionale per il test EGFR a favore del paziente e del clinico. / Fenizia, Francesca; Pinto, Carmine; De Rosa, Gaetano; Barberis, Massimo; Marchetti, Antonio; Normanno, Nicola.

In: Rassegna di Patologia dell'Apparato Respiratorio, Vol. 30, No. 1, 01.01.2015, p. 32-36.

Research output: Contribution to journalArticle

@article{9ea5c552ddb349fc9f543582a7b6cc29,
title = "FASTnet: una piattaforma nazionale per il test EGFR a favore del paziente e del clinico",
abstract = "During the last decade, new drugs able to interfere with specific neoplastic processes have been developed. Therefore, the possibility of creating a personalized therapeutic scheme, based on the molecular alterations activated in each single tumor, is becoming a clinical reality. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung tumor, representing about 80{\%} of pulmonary cancers. Following the discovery of the role of EGFR gene in tumor growth and development and, later, of activating mutations of this gene, new targeted therapies have been introduced in clinical practice, namely inhibitors of the EGFR tirosin-kinase domain (TKI). First line treatment with TKIs is considered the optimal therapy in patients with metastatic or locally advanced EGFR-M+ NSCLC. For this reason, it is crucial to evaluate EGFR mutational status to identify the most suitable therapeutic approach. The EGFR FASTnet program, started in 2010 with the support of AstraZeneca, is a national network designed to facilitate the exchange of biological material, clinico-pathological data and diagnostic reports between medical oncologists, primary pathologists and referral laboratories through a dedicated website (www.egfrfastnet. it), a call-center and a courier. Starting from July 2010, 12.893 FASTnet forms have been completed and, up to date, 677 oncologists, 153 primary pathologists and 25 analysts are registered to the network and give their active contribute to the mutational analysis workflow. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology - Italian division of International Academy of Pathology (SIAPeC-IAP) have full access to the anonymous EGFR FASTnet database that provides relevant information on molecular pathology in lung cancer in Italy.",
keywords = "EGFR mutations, FASTnet, NSCLC, Personalised therapy",
author = "Francesca Fenizia and Carmine Pinto and {De Rosa}, Gaetano and Massimo Barberis and Antonio Marchetti and Nicola Normanno",
year = "2015",
month = "1",
day = "1",
language = "Italian",
volume = "30",
pages = "32--36",
journal = "Rassegna di Patologia dell'Apparato Respiratorio",
issn = "0033-9563",
publisher = "EdiAipo Scientifica s.c.a.r.l",
number = "1",

}

TY - JOUR

T1 - FASTnet

T2 - una piattaforma nazionale per il test EGFR a favore del paziente e del clinico

AU - Fenizia, Francesca

AU - Pinto, Carmine

AU - De Rosa, Gaetano

AU - Barberis, Massimo

AU - Marchetti, Antonio

AU - Normanno, Nicola

PY - 2015/1/1

Y1 - 2015/1/1

N2 - During the last decade, new drugs able to interfere with specific neoplastic processes have been developed. Therefore, the possibility of creating a personalized therapeutic scheme, based on the molecular alterations activated in each single tumor, is becoming a clinical reality. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung tumor, representing about 80% of pulmonary cancers. Following the discovery of the role of EGFR gene in tumor growth and development and, later, of activating mutations of this gene, new targeted therapies have been introduced in clinical practice, namely inhibitors of the EGFR tirosin-kinase domain (TKI). First line treatment with TKIs is considered the optimal therapy in patients with metastatic or locally advanced EGFR-M+ NSCLC. For this reason, it is crucial to evaluate EGFR mutational status to identify the most suitable therapeutic approach. The EGFR FASTnet program, started in 2010 with the support of AstraZeneca, is a national network designed to facilitate the exchange of biological material, clinico-pathological data and diagnostic reports between medical oncologists, primary pathologists and referral laboratories through a dedicated website (www.egfrfastnet. it), a call-center and a courier. Starting from July 2010, 12.893 FASTnet forms have been completed and, up to date, 677 oncologists, 153 primary pathologists and 25 analysts are registered to the network and give their active contribute to the mutational analysis workflow. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology - Italian division of International Academy of Pathology (SIAPeC-IAP) have full access to the anonymous EGFR FASTnet database that provides relevant information on molecular pathology in lung cancer in Italy.

AB - During the last decade, new drugs able to interfere with specific neoplastic processes have been developed. Therefore, the possibility of creating a personalized therapeutic scheme, based on the molecular alterations activated in each single tumor, is becoming a clinical reality. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung tumor, representing about 80% of pulmonary cancers. Following the discovery of the role of EGFR gene in tumor growth and development and, later, of activating mutations of this gene, new targeted therapies have been introduced in clinical practice, namely inhibitors of the EGFR tirosin-kinase domain (TKI). First line treatment with TKIs is considered the optimal therapy in patients with metastatic or locally advanced EGFR-M+ NSCLC. For this reason, it is crucial to evaluate EGFR mutational status to identify the most suitable therapeutic approach. The EGFR FASTnet program, started in 2010 with the support of AstraZeneca, is a national network designed to facilitate the exchange of biological material, clinico-pathological data and diagnostic reports between medical oncologists, primary pathologists and referral laboratories through a dedicated website (www.egfrfastnet. it), a call-center and a courier. Starting from July 2010, 12.893 FASTnet forms have been completed and, up to date, 677 oncologists, 153 primary pathologists and 25 analysts are registered to the network and give their active contribute to the mutational analysis workflow. The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology - Italian division of International Academy of Pathology (SIAPeC-IAP) have full access to the anonymous EGFR FASTnet database that provides relevant information on molecular pathology in lung cancer in Italy.

KW - EGFR mutations

KW - FASTnet

KW - NSCLC

KW - Personalised therapy

UR - http://www.scopus.com/inward/record.url?scp=84928319358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928319358&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:84928319358

VL - 30

SP - 32

EP - 36

JO - Rassegna di Patologia dell'Apparato Respiratorio

JF - Rassegna di Patologia dell'Apparato Respiratorio

SN - 0033-9563

IS - 1

ER -